Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Keros Therapeutics, Inc. (Nasdaq: KROS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Keros’ clinical programs, capital allocation decisions, governance changes and financial condition.
As a clinical-stage biopharmaceutical company focused on TGF-ß pathway therapeutics, Keros uses its SEC filings to report material events related to its lead product candidate KER-065 and its most advanced candidate elritercept. Form 8-K reports have covered topics such as additional clinical data from a Phase 1 trial of KER-065, U.S. Food and Drug Administration Orphan Drug designation for KER-065 in Duchenne muscular dystrophy, and corporate updates regarding the prioritization of KER-065 and discontinuation of internal development of cibotercept (KER-012).
Filings also document Keros’ capital return program and share repurchase activity. Recent 8-Ks describe stock purchase agreements with entities affiliated with ADAR1 Capital Management and Pontifax Venture Capital, the planned and completed cash tender offer to repurchase a substantial number of shares of common stock at a fixed price, and related governance changes. Other reports furnish quarterly financial results, including revenue from a global license agreement with Takeda Pharmaceuticals U.S.A., Inc. related to elritercept, research and development spending and cash and cash equivalents.
On this page, users can review real-time updates as new KROS filings are posted to EDGAR, including Forms 8-K, 10-Q and 10-K when available, as well as exhibits such as press releases and corporate presentations. Stock Titan’s AI-powered tools summarize lengthy filings, highlight key sections and help explain complex topics like capital return structures, executive employment agreements and risk factor disclosures in more accessible language.
For those analyzing Keros’ development strategy, financial runway, licensing arrangements or governance, the SEC filings page serves as a primary source of company-sanctioned information. It allows investors and researchers to trace how Keros reports progress on its TGF-ß–focused pipeline, documents material agreements and communicates significant corporate events over time.
Keros Therapeutics calls its 2026 annual meeting for June 3, 2026, asking stockholders to elect two Class III directors, ratify Deloitte & Touche LLP as auditor for 2026, and approve an advisory “say‑on‑pay” vote on executive compensation.
The proxy also describes a major strategic realignment in 2025, with Keros discontinuing material internal development of cibotercept to focus on its lead program, rinvatercept, targeting Duchenne muscular dystrophy and other neuromuscular diseases. The company highlights encouraging Phase 1 data, plans for Phase 2 trials in DMD and ALS, and an ALS collaboration within the Healey ALS MyMatch program.
Keros reports completing a $375 million capital return program through share repurchases, including a tender offer, while indicating it preserved flexibility to fund key clinical priorities. The filing outlines ongoing board refreshment, recent director changes and an independent chair structure, alongside detailed descriptions of board committees, governance practices and stockholder voting mechanics.
Keros Therapeutics director Jean Jacques Bienaimé made an open-market purchase of the company’s common stock. On April 15, 2026, he bought 1,000 shares at a weighted average price of $11.70 per share, increasing his direct holdings to 8,450 shares.
The shares were purchased under a Rule 10b5-1 trading plan that Bienaimé adopted on December 5, 2025. The filing notes the trade was executed through multiple transactions at prices between $11.56 and $11.80 per share.
Keros Therapeutics Schedule 13G reports that BlackRock, Inc. beneficially owned 1,990,842 shares of common stock, representing 10.1% of the class as of 03/31/2026. The filing attributes ownership to certain Reporting Business Units of BlackRock and shows 1,960,306 shares with sole voting power.
The filing states that various persons may have rights to dividends or sale proceeds and that no single outside person holds more than 5% separately. The filing is signed by a BlackRock managing director on 04/07/2026.
Keros Therapeutics chief executive officer Jasbir Seehra exercised employee stock options to acquire 55,000 shares of common stock at an exercise price of $0.30 per share on April 2, 2026. These options were immediately exercisable. Following the transaction, he directly owned 440,708 shares of common stock.
Keros Therapeutics reported that Chief Legal Officer Esther Cho received a grant of employee stock options covering 80,000 shares of common stock. The options have an exercise price of $15.52 per share and expire on February 23, 2036. One quarter of the options vest on February 24, 2027, with the remaining shares vesting in twelve substantially equal quarterly installments, contingent on her continued service. This is a compensation-related award rather than an open‑market purchase.
Keros Therapeutics Inc — Schedule 13G/A amendment filed by The Vanguard Group. The amendment states that, after an internal realignment under SEC Release No. 34-39538, The Vanguard Group reports 0 shares beneficially owned, representing 0% of Keros common stock. The filing explains certain subsidiaries will report holdings separately.
Keros Therapeutics director Charles W. Newton received new equity awards. He was granted stock options covering 14,788 shares of Common Stock at an exercise price of $11.35 per share, expiring on March 8, 2036, and 13,215 restricted stock units.
The RSUs vest over three years in twelve equal quarterly installments starting on May 15, 2026, while the options vest over three years in equal quarterly installments starting on June 9, 2026, in each case subject to his continuous service. Following these awards, he directly holds 14,788 options and 13,215 shares.
Keros Therapeutics, Inc. director Charles W. Newton has filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting insider of the company and records his starting position for future ownership and transaction disclosures.